Medtech / devices
Benign prostatic hyperplasia (BPH) is a rapidly growing urological concern driven by a global ageing population. With healthcare systems under strain due to increased demand, resource limitations, and surgical backlogs, hospitals may benefit from technologies that are less invasive for patients and less resource intensive for healthcare systems. Among minimally invasive treatments for BPH, Rezūm™ [...]
A new experimental drug called IC7Fc could help treat both diabetes and heart disease by lowering cholesterol and reducing inflammation in the arteries, researchers have found. In tests on mice prone to cardiovascular disease, the drug significantly reduced blood fats (triglycerides) and cholesterol while slowing the build-up of fatty deposits in arteries that can cause [...]
Age Tech World explores the latest business developments in the world of age technology and longevity US$25m fund to reimagine human longevity India-based entrepreneur Deepinder Goyal has announced the launch of Continue Research, supported by a US$25m personal fund dedicated to advancing global longevity science. Continue Research was founded two years ago as an independent [...]
AlayaCare has acquired Nightingale Software to expand its aged care footprint in Australia and New Zealand, pending customary conditions and regulatory approvals. AlayaCare Nightingale’s platform will continue to operate and staff will be retained, with services supported by AlayaCare’s technology, product roadmap and resources. The company says its all-in-one platform offers real-time data insights, personalised [...]
The UK government has announced a plan to diagnose 92 per cent of people with dementia within 18 weeks of a doctor’s referral by 2029 — up from fewer than half today. A £5m research challenge will fund new diagnostic tools, including blood tests, saliva analysis and AI-driven technologies, to speed up detection and improve [...]
Czech company H₂ Medical Technologies, a subsidiary of H₂ Global Group, has received official approval from the State Institute for Drug Control (SÚKL) to begin a clinical study on molecular hydrogen inhalation therapy for patients with mild cognitive impairment (MCI), an early stage of Alzheimer’s disease. The authorisation marks Europe’s first fully approved clinical trial [...]
Canada has conditionally approved Leqembi (lecanemab), the first treatment that targets an underlying cause of early Alzheimer’s disease by removing toxic amyloid beta proteins from the brain. Health Canada issued the Notice of Compliance with Conditions on 27 October for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have confirmed [...]
Bright light at night raises the risk of heart attack by 47 per cent and heart failure by 56 per cent, according to research involving nearly 89,000 people. Being exposed to bright light at night could significantly increase the chances of developing serious heart problems, including heart attacks, strokes and heart failure. The largest study [...]
Researchers have shown that new TOR inhibitor rapalink-1 prolongs lifespan in fission yeast, offering insight into how drugs may slow ageing. Rapalink-1, a next-generation TOR inhibitor currently under investigation for cancer therapy, slowed cell growth and significantly extended lifespan in yeast models, acting through TORC1 — the growth-promoting arm of the TOR pathway. The TOR [...]
Researchers in Denmark have discovered why the APOE4 gene increases Alzheimer’s risk — by preventing brain cells from switching from glucose to fats for energy as they age. The study found that as brain cells grow older and lose efficiency in using glucose — their main energy source — they can normally switch to burning [...]
